Search - tctmd.com

Displaying 461 - 480 of 522

Sort: Relevancy | Date

News Daily News

Nonvalvular A-fib Patients More Likely to Remain on Dabigatran Than Warfarin

Jason Kahn

August 12, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

News Daily News

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Jason Kahn

August 05, 2013

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

News Daily News

Oral Anticoagulant Use for A-fib in Community Practice Appears Appropriate

June 21, 2013

News Daily News

El Uso de Anticoagulantes Orales contra la FA en Prácticas de la Comunidad parece Apropiado

June 21, 2013

Presentation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Presenter: MW Cullen

June 20, 2013

News Daily News

Oclusión de LAA más rentable que la warfarina y que el dabigatran para pacientes con fibrilación auricular

Yael L. Maxwell

June 07, 2013

News Daily News

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

Yael L. Maxwell

June 07, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

Presentation TCT 2012

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Presenter: Paddy Barrett

October 25, 2012

News Daily News

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

October 19, 2012

Advertisement

Nonvalvular A-fib Patients More Likely to Remain on Dabigatran Than Warfarin

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Apixaban Reduce el Índice de Hospitalizaciones compardo con la Aspirina en Pacientes con Fibrilación Auricular

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Oral Anticoagulant Use for A-fib in Community Practice Appears Appropriate

El Uso de Anticoagulantes Orales contra la FA en Prácticas de la Comunidad parece Apropiado

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Oclusión de LAA más rentable que la warfarina y que el dabigatran para pacientes con fibrilación auricular

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

4q25 and Prediction of Atrial Fibrillation: How Can This Information Help the Clinician?

Una Nueva Clase de Anticoagulantes Orales resulta Segura comparada con la Warfarina para Pacientes con FA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content